Forecasts data is unavailable for this security.
Consensus recommendation
- 19-Sep-24
- 17-Oct-24
- 07-Nov-24
Select bar for recommendation details.
Recommendations | 07-Nov-24 | |
---|---|---|
Buy | 3 | |
Outperform | 3 | |
Hold | 0 | |
Sell | 0 | |
Strong Sell | 0 |
Share price forecast in USD
The 6 analysts offering 12 month price targets for Arrivent Biopharma Inc have a median target of 38.00, with a high estimate of 41.00 and a low estimate of 36.00. The median estimate represents a 11.14% increase from the last price of 34.19.
High | 19.9% | 41.00 |
Med | 11.1% | 38.00 |
Low | 5.3% | 36.00 |
Earnings history & estimates in USD
Average growth rate | +7.14% |
More ▼
Revenue history & estimates in USD
Average growth rate | 0.00% |
More ▼